General Investing >> Analyst Interviews >> March 15, 2004
EARLY-STAGE TECHNOLOGY VENTURE CAPITAL: ROBERT NELSEN – ARCH VENTURE PARTNERS
ROBERT NELSEN is Managing Director and Co-Founder of ARCH Venture
Partners. ARCH Venture Partners is one of the US's leading early-stage
technology venture capital firms, with over $900 million under
management. Mr. Nelsen concentrates on new company creation from early
stage technologies originating from universities and national
laboratories with a special concentration in life sciences. He led the
formation and initial funding round of Everyday Learning Corporation,
Adolor Corporation, Netbot, Inc. and Optobionics Corporation. Mr.
Nelsen was also responsible for ARCH's early investments in Aviron,
Inc., Caliper Life Seciences, Illumina, Inc., deCode Genetics,Inc.,
GenVec, Inc., Genomica Corporation, Alnylam, Inc., Xenoport, Inc.,
Neurogesx, Inc., Xcyte Therapies, Inc., R2 Technology, Inc., Elixir,
Array BioPharma, Inc., Trubion, Inc., Surface Logix and Amphora. Mr.
Nelsen is a past or present director of Adolor Corporation Caliper Life
Sciences (CALP), Xcyte Therapies, Inc., Illumina, Inc. (ILMN), Everyday
Learning Corporation, and was Chairman of Netbot, Inc. He holds a BS in
Biology and Economics from The University of Puget Sound and an MBA from
The University of Chicago. Profile
TWST: What is ARCH Venture Partners and what are its recent activities?
Mr. Nelsen: ARCH is an early-stage technology investor, probably one of